Humanized anti-IL-5 antibody therapy

ME Rothenberg - Cell, 2016 - cell.com
Cell, 2016cell.com
Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an
eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are
effective in treating asthma patients with the severe eosinophilic form of the disease and are
the first new class of asthma drugs approved in 12 years.
Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years.
cell.com